Home  >  TopNews
Eppen_Protein_LoBind_Nov26
you can get e-magazine links on WhatsApp. Click here
Education + Font Resize -

Faculties aggressively working to equip students with core scientific knowledge & digital skills to be future-ready

Nandita Vijayasimha, Bengaluru
Thursday, August 20, 2026, 08:00 Hrs  [IST]

Faculties in pharmacy colleges are now aggressively working to equip students with core scientific knowledge and digital skills to be future-ready. This is close on the heels of Pharmacy Council of India (PCI) revised B.Pharm syllabus aligned with the National Education Policy (NEP) 2020, effective from 2026–27.

The major changes are new technology-oriented subjects: Python Programming, Applied Biostatistics, Data Analytics, Machine Learning (ML), and Artificial intelligence (AI) applications. There is mandatory internships and greater flexibility with electives and specialisations. Further, AI and ML are transforming the entire pharmaceutical value chain.

For instance, in Drug Discovery & Design, there is focus on virtual screening, generative molecule design, and toxicity prediction. We are providing a peek into sensors, anomaly detection and predictive maintenance. In clinical trials & pharmacovigilance, now requires smarter patient selection and faster data analysis. Even supply chain and retail demand forecasting and inventory optimization, said Prof. R Raveendra, head, Department of Pharmaceutical Chemistry, MIT College of Pharmacy, Mysuru.  

There is a huge perception gap.  Engineering, Medicine, and Civil Services enjoy higher social visibility and perceived glamour. Pharma is often viewed as “less prestigious” or limited to sales/retail roles, despite being a critical pillar of healthcare. There are several employment opportunities spanning from manufacturing, QA/QC, R&D, Clinical Research, Pharmacovigilance, Regulatory Affairs, Hospital & Community Pharmacy, Medical Writing, Sales & Marketing, Drug Inspector in the Government, Academia, and Entrepreneurship. Now the NEP 2026 syllabus integrates digital skills (Python, AI/ML), mandatory practical industry exposure, research projects, and an entrepreneurship focus. Core subjects include Pharmaceutics, Chemistry, Pharmacology and Pharmacognosy, he added.

Post the Covid pandemic, several changes have occurred in India’s pharma sector. This pandemic has highlighted India’s role as the pharmacy of the world while exposing supply-chain vulnerabilities especially dependence on Chinese APIs/KSMs. Post-pandemic, the sector shifted from pure volume-driven generics toward value-added products, self-reliance and innovation, Prof, Raveendra said.

There have been key changes too like the production linked incentive (PLI) schemes that have propelled domestic manufacturing of critical APIs and intermediates.  It resulted in strong growth in turnover touching Rs. 4,71,898 crore in FY2024-25. There is a visible shift towards higher-value products, complex generics, biosimilars, specialty drugs. Further, the industry’s infrastructure strength shows 752 US FDA-approved sites, 2,050 WHO-GMP plants. The market trajectory projects revenues of $100+ billion by 2030 and $450–500 billion by 2047, he said.

The ecosystem includes digital pharmacy with PharmEasy, Tata 1mg, AI drug discovery with Peptris Technologies, Boltzmann Labs, and B2B pharma-tech with MEDdelivery.  

Besides, entrepreneurship modules with incubators, and focus on high-impact areas like AI and biosimilars enables us to help build future-ready skills, master core science and digital competencies. There is practical exposure to pursue internships in various settings. We are helping to make students stay curious, ethical, and ensuring our guidance is long-term oriented, said Prof. Raveendra.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
API_China2026
Copyright © 2024 Saffron Media Pvt. Ltd | twitter
 
linkedin
 
 
linkedin
 
instagram